dato-dxd triple negative breast cancer

Release time ：Dec-22,2024

Ductal Carcinoma In Situ (DCIS) represents an early stage of breast cancer confined to the milk ducts without spreading to adjacent tissues. Triple Negative Breast Cancer (TNBC) is a distinct subtype of breast cancer, defined by the absence of estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER2) on cancer cells. While these two breast cancer types are distinct, both pose significant health risks to women. Patients diagnosed with DCIS that is also TNBC often face more complex treatment scenarios, as TNBC tends to be less responsive to conventional endocrine and targeted therapies, with chemotherapy being the primary treatment option. However, early detection and a multimodality approach to treatment, including surgery, radiotherapy, and neoadjuvant chemotherapy, can substantially enhance patient survival rates. Given the high heterogeneity of TNBC, researchers are actively investigating novel therapeutic strategies such as immunotherapy and PARP inhibitors to expand treatment options for patients. For patients with DCIS who have TNBC, it is advised to vigilantly monitor disease progression and adhere to a standardized treatment regimen under medical supervision. Additionally, maintaining healthy lifestyle practices, including a balanced diet, regular physical activity, and abstaining from smoking and alcohol, can contribute to better therapeutic outcomes and overall quality of life. Crucially, patients should actively engage in regular follow-ups and check-ups with their healthcare providers to promptly identify and address any emerging issues.